Keywords: early-stage, spending, up, nmes, plummet, says, report

Early-stage R&D spending up, but NMEs plummet, says report

Article | 18 August 2003

Print This

New drug approvals have fallen from 53 New Molecular Entities approved in 1996 to just 26 last year. Simultaneously, R&D spending has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in